Aadi Bioscience Files Proxy Materials
Ticker: WHWK · Form: DEFA14A · Filed: Feb 19, 2025 · CIK: 1422142
Sentiment: neutral
Topics: proxy-statement, corporate-governance, filing-update
Related Tickers: AADI
TL;DR
AADI filed proxy docs, formerly Aerpio Pharma. Shareholders, pay attention!
AI Summary
Aadi Bioscience, Inc. filed a Definitive Additional Materials proxy statement on February 19, 2025. This filing relates to the company's Schedule 14A, which is a proxy statement used for shareholder meetings. The company was formerly known as Aerpio Pharmaceuticals, Inc. and Zeta Acquisition Corp II.
Why It Matters
Proxy statements are crucial for shareholders as they contain important information about company proposals, executive compensation, and voting procedures, enabling informed participation in corporate governance.
Risk Assessment
Risk Level: low — This filing is a routine proxy statement and does not contain information that inherently increases risk for investors.
Key Players & Entities
- Aadi Bioscience, Inc. (company) — Registrant
- Aerpio Pharmaceuticals, Inc. (company) — Former Company Name
- ZETA ACQUISITION CORP II (company) — Former Company Name
- 20250219 (date) — Filing Date
FAQ
What type of filing is this?
This is a DEFA14A filing, specifically 'Definitive Additional Materials' for a proxy statement.
Who is the filing company?
The filing company is Aadi Bioscience, Inc.
When was this filing made?
The filing was made on February 19, 2025.
What were Aadi Bioscience's former names?
Aadi Bioscience, Inc. was formerly known as Aerpio Pharmaceuticals, Inc. and Zeta Acquisition Corp II.
What is the purpose of a Schedule 14A filing?
A Schedule 14A filing is a proxy statement filed with the SEC to solicit shareholder votes on important corporate matters.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on February 19, 2025 regarding Aadi Bioscience, Inc. (WHWK).